Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01093573|
Recruitment Status : Active, not recruiting
First Posted : March 26, 2010
Last Update Posted : June 10, 2016
|Condition or disease||Intervention/treatment||Phase|
|Untreated Adult Acute Myeloid Leukemia||Drug: midostaurin Drug: azacitidine Other: laboratory biomarker analysis Other: bone marrow aspiration Other: liquid chromatography Other: flow cytometry Other: mutation analysis Other: pharmacological study Other: mass spectrometry Other: protein expression analysis||Phase 1 Phase 2|
I. To determine the safe and tolerable dose of midostaurin in combination with azacitidine in patients with acute myelogenous leukemia. (Phase I) II. To describe the toxicity profile of the combination of midostaurin and azacitidine in patients with acute myelogenous leukemia. (Phase I/II) III. To determine the complete and partial response rate and rate of hematologic improvement of midostaurin and 5-azacitidine in untreated acute myelogenous leukemia. (Phase I/II)
I. To describe pharmacokinetics of oral midostaurin given in combination with azacitidine on a day 8-21 schedule. (Phase I/II) II. To correlate treatment response with FLT3 mutational status in a descriptive fashion. (Phase I/II) III. To assess overall survival of patients from initiation of midostaurin-azacitidine toxicities. (Phase I/II) IV. To determine median disease-free survival of the regimen in untreated patients. (Phase II)
I. To describe signaling in CD117+ committed myeloid precursors in whole blood and bone marrow samples before and during treatment. (Phase I/II) II. To measure in vivo FLT3 inhibition using plasma inhibition assay (PIA) and Flt ligand (FL) levels in patients enrolled on this trial before and during treatment. (Phase I/II)
OUTLINE: This is a phase I, dose escalation study of midostaurin followed by a phase II study.
Patients receive azacitidine intravenously (IV) over 10-20 minutes on days 1-7 and midostaurin orally (PO) twice daily (BID) on days 8-21. Courses repeat every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||34 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Study of Midostaurin (PKC412) and 5-Azacitidine for Elderly Patients With Acute Myelogenous Leukemia.|
|Study Start Date :||July 2009|
|Actual Primary Completion Date :||June 2016|
Experimental: Arm I
Patients receive azacitidine IV over 10-20 minutes on days 1-7 and oral midostaurin twice daily on days 8-21.
Other Names:Drug: azacitidine
Other Names:Other: laboratory biomarker analysis
Correlative studyOther: bone marrow aspiration
Correlative studyOther: liquid chromatography
Other Name: LCOther: flow cytometry
Correlative studyOther: mutation analysis
Correlative studyOther: pharmacological study
Other Name: pharmacological studiesOther: mass spectrometry
Correlative studyOther: protein expression analysis
- Maximum tolerated dose of midostaurin in combination with azacitidine in patients with acute myelogenous leukemia (Phase I) [ Time Frame: Day 28 ]Defined as the dose level below 1 of 3 then 2 of 3 patients experience dose-limiting toxicity (DLT).
- Rate of hematologic improvement [ Time Frame: 2 months ]Hematologic toxicity: For patients with ANC > 500/ μl at baseline, dose modifications will be made accordingly. Recovery is defined as neutrophil count > 500/ul if neutrophils nadir is below 500/ul: Hematologic response will be assessed on day 1 of each cycle of azacitidine.
- Complete and partial response rate of midostaurin and azacitidine in untreated acute myelogenous leukemia (Phase I/II) [ Time Frame: after 4 months of treatment ]Response will be assessed using the standard morphologic criteria for acute leukemia as follows: Complete remission (CR): ANC ≥ 1000/ uL and platelets of > 100,000/ uL without circulating blasts and bone marrow with < 5% blasts and no Auer rods; Partial remission (PR): This designation requires at least a 50% decrease in the bone marrow blasts to 5-25%.
- Pharmacokinetic profile of midostaurin given with azacitidine (Phase I) [ Time Frame: Before dosing of midostaurin on days 8, 15, and 21 of courses 1 and 2 ]
- Time to disease progression [ Time Frame: Up to 3 years ]The Kaplan-Meier method will be used to estimate survivor function.
- Changes of phosphorylation status of FLT3 in blood and bone marrow samples (Phase I/II) [ Time Frame: Baseline to 4 cycles (16 weeks) ]
- Overall survival (Phase I/II) [ Time Frame: Up to 3 years ]The Kaplan-Meier method will be used to estimate survivor function.
- To correlate treatment response with FLT3 mutational status in a descriptive fashion.(Phase I) [ Time Frame: Baseline to 4 cycles (16 weeks) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01093573
|United States, Ohio|
|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center|
|Cleveland, Ohio, United States, 44106|
|United States, West Virginia|
|West Virginia University|
|Morgantown, West Virginia, United States, 26506|
|Principal Investigator:||Brenda Cooper, MD||Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center|